Altimmune Inc.
ALT | NASDAQ
$3.27
+$0.02 (+0.62%)
At close: Sep 21, 2026, 4:00 PM ET
$3.30
+$0.03 (+0.92%)
Pre-market:
Sep 22, 2026, 6:06 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 41K | 20K | 426K | -68K | 4.41M | 8.19M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 33.51M |
Gross Profit | 41K | 20K | 426K | -68K | 4.41M | -25.32M |
Operating Income | -94.49M | -103.17M | -95.93M | -87.74M | -96.91M | -54.8M |
Interest Income | 7.54M | 8.07M | 7.35M | 2.87M | 203K | 322.51K |
Pretax Income | -88.77M | -95.06M | -88.45M | -84.91M | -97.09M | -43.63M |
Net Income | -88.09M | -95.06M | -88.45M | -84.71M | -97.09M | -49.04M |
Selling & General & Admin | 28.1M | 20.97M | 18.14M | 17.13M | 15.41M | 13.21M |
Research & Development | 66.43M | 82.23M | 65.8M | 70.54M | 74.54M | 49.77M |
Other Expenses | n/a | n/a | 12.42M | n/a | 11.37M | -33.51M |
Operating Expenses | 94.53M | 103.19M | 96.36M | 87.67M | 101.32M | 29.47M |
Interest Expense | 1.64M | 9K | 35K | 8K | 5K | 9.42K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 94.53M | 103.19M | 96.36M | 87.67M | 101.32M | 62.98M |
Income Tax Expense | -681K | n/a | n/a | -197K | n/a | 5.42M |
Shares Outstanding (Basic) | 88.1M | 71M | 53.25M | 46.93M | 41.28M | 25.64M |
Shares Outstanding (Diluted) | 88.1M | 71M | 53.25M | 46.93M | 41.28M | 25.64M |
EPS (Basic) | -1 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 |
EPS (Diluted) | -1 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 |
EBITDA | -87.03M | -94.81M | -87.94M | -84.41M | -96.53M | -38.1M |
EBIT | -87.14M | -95.05M | -88.41M | -84.9M | -97.09M | -38.53M |
Depreciation & Amortization | 112K | 238K | 477K | 493K | 551K | 428.88K |
Add to Watchlist
Select watchlists to add or remove ALT